Psychedelics as potential mental health treatment are explored by Trump administration: clinical trials highlight MDMA and psilocybin for PTSD and depression

Psychedelics for mental health care are being explored by the Trump administration, with officials linking interest to potential treatment options for PTSD, depression, addiction, and other debilitating conditions. The article cites statements from US Department of Health and Human Services and the Department of Veterans Affairs, including claims that the VA is running 11 psychedelic clinical trials involving about 800 veterans. It also references an example where MDMA was used in a clinical trial and the participant reported PTSD symptom relief. Clinical evidence discussed centers on MDMA and psilocybin, including claims about psilocybin-assisted therapy’s progress and an MDMA study describing benefits like empathy, trust, self-compassion, and a therapeutic “window of tolerance.” The piece also emphasizes risks of unregulated or recreational use, noting potential anxiety and paranoia during psychedelic experiences, and calls for careful medical oversight and monitoring in clinical settings.